

Tobias Maurer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5105611/publications.pdf>

Version: 2024-02-01

178
papers

11,633
citations

26630

56
h-index

30922

102
g-index

209
all docs

209
docs citations

209
times ranked

8695
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Hybrid ⁶⁸ Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 668-674.	5.0	907
2	Diagnostic Efficacy of ⁶⁸ Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. <i>Journal of Urology</i> , 2016, 195, 1436-1443.	0.4	659
3	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>Cancer Cell</i> , 2016, 30, 27-42.	16.8	486
4	Current use of PSMA- ⁶⁸ PET in prostate cancer management. <i>Nature Reviews Urology</i> , 2016, 13, 226-235.	3.8	469
5	Simultaneous ⁶⁸ Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. <i>European Urology</i> , 2016, 70, 829-836.	1.9	456
6	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 469-478.	5.0	372
7	Comparison of bone scintigraphy and ⁶⁸ Ga-PSMA PET for skeletal staging in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2114-2121.	6.4	302
8	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. <i>Radiographics</i> , 2018, 38, 200-217.	3.3	262
9	Detection Efficacy of ¹⁸ F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 362-368.	5.0	238
10	Value of ⁶⁸ Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1713-1719.	5.0	213
11	Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. <i>Journal of Clinical Investigation</i> , 2015, 125, 26.		206
12	Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with ¹⁷⁷ Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 920-926.	1.9	206
13	^{99m} Tc-based Prostate-specific Membrane Antigen- ⁶⁸ radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 75, 659-666.	1.9	195
14	Prostate-specific Membrane Antigen- ⁶⁸ radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. <i>European Urology</i> , 2015, 68, 530-534.	1.9	192
15	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7448-7454.	7.0	190
16	⁶⁸ Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. <i>Cancer Imaging</i> , 2016, 16, 14.	2.8	171
17	Preclinical Evaluation and First Patient Application of ^{99m} Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 235-242.	5.0	170
18	Systemic Radioligand Therapy with ¹⁷⁷ Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 382-391.	0.4	166

#	ARTICLE	IF	CITATIONS
19	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 67S-76S.	5.0	163
20	Matched-Pair Comparison of ⁶⁸ Ga-PSMA-11 PET/CT and ¹⁸ F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 51-57.	5.0	161
21	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. <i>Nature Communications</i> , 2021, 12, 2301.	12.8	159
22	CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. <i>European Journal of Immunology</i> , 2002, 32, 2356.	2.9	158
23	Radiation Dosimetry for ¹⁷⁷ Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2017, 58, 445-450.	5.0	144
24	A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 47-76.	5.4	140
25	Efficacy, Predictive Factors, and Prediction Nomograms for ⁶⁸ Ga-labeled Prostate-specific Membrane Antigen- ⁶⁸ Ga-PSMA-11 PET/CT in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 656-661.	1.9	129
26	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 469-476.	6.4	119
27	Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. <i>Scientific Reports</i> , 2017, 7, 395.	3.3	117
28	⁶⁸ Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 367-371.	5.0	112
29	⁶⁸ Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623.	5.0	111
30	Detection of circulating tumor cells in different stages of prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 755-763.	2.5	108
31	Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1486-1499.	6.4	107
32	Preliminary results on response assessment using ⁶⁸ Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 602-612.	6.4	107
33	⁶⁸ Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1406-1411.	5.0	106
34	The Sensitivity of [11C]Choline PET/CT to Localize Prostate Cancer Depends on the Tumor Configuration. <i>Clinical Cancer Research</i> , 2011, 17, 3751-3759.	7.0	103
35	Intravascular volume therapy in adults. <i>European Journal of Anaesthesiology</i> , 2016, 33, 488-521.	1.7	95
36	Cutting Edge: Toll-Like Receptor 9 Expression Is Not Required for CpG DNA-Aided Cross-Presentation of DNA-Conjugated Antigens but Essential for Cross-Priming of CD8 T Cells. <i>Journal of Immunology</i> , 2003, 170, 2802-2805.	0.8	92

#	ARTICLE	IF	CITATIONS
37	⁶⁸ Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. <i>Prostate</i> , 2017, 77, 920-927.	2.3	89
38	[¹¹¹ In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. <i>EJNMMI Research</i> , 2015, 5, 68.	2.5	88
39	Value of ¹¹¹ In-prostate-specific membrane antigen (¹¹¹ In-PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. <i>BJU International</i> , 2017, 120, 40-47.	2.5	88
40	Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 76, 517-523.	1.9	81
41	Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [¹¹ C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 694-701.	6.4	79
42	Integration of ⁶⁸ Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. <i>Radiation Oncology</i> , 2016, 11, 73.	2.7	79
43	Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups. <i>Clinical Cancer Research</i> , 2018, 24, 1586-1593.	7.0	79
44	Diagnostic Efficacy of [¹¹ C]Choline Positron Emission Tomography/Computed Tomography Compared With Conventional Computed Tomography in Lymph Node Staging of Patients With Bladder Cancer Prior to Radical Cystectomy. <i>European Urology</i> , 2012, 61, 1031-1038.	1.9	75
45	⁶⁸ Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. <i>Abdominal Imaging</i> , 2015, 40, 1769-1771.	2.0	74
46	Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. <i>European Urology</i> , 2017, 72, 461-469.	1.9	74
47	The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. <i>World Journal of Urology</i> , 2016, 34, 181-187.	2.2	73
48	Recent advances in nuclear and hybrid detection modalities for image-guided surgery. <i>Expert Review of Medical Devices</i> , 2019, 16, 711-734.	2.8	71
49	The use of PET/CT in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 4-21.	3.9	70
50	¹⁸ F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 696-701.	5.0	67
51	Biodistribution and radiation dosimetry of ⁶⁸ Ga-PSMA HBED CCa PSMA specific probe for PET imaging of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1962-1970.	6.4	66
52	Detection Efficacy of Hybrid ⁶⁸ Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1081-1087.	5.0	66
53	Robot-assisted laparoscopic surgery using DROP-IN radioguidance: first-in-human translation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 49-53.	6.4	65
54	Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 159-171.	3.8	62

#	ARTICLE	IF	CITATIONS
55	Restricted Water Diffusibility as Measured by Diffusion-weighted MR Imaging and Choline Uptake in ¹¹ C-Choline PET/CT are Correlated in Pelvic Lymph Nodes in Patients with Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2011, 13, 352-361.	2.6	61
56	Intense PSMA-expression using ⁶⁸ Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 193-194.	6.4	61
57	Inguinal lymph node dissection: Epidermal vacuum therapy for prevention of wound complications. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2013, 66, 390-396.	1.0	60
58	Multimodal image-guided prostate fusion biopsy based on automatic deformable registration. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2015, 10, 1997-2007.	2.8	60
59	A DROP-IN Gamma Probe for Robot-assisted Radioguided Surgery of Lymph Nodes During Radical Prostatectomy. <i>European Urology</i> , 2021, 79, 124-132.	1.9	58
60	Topography of Lymph Node Metastases in Prostate Cancer Patients Undergoing Radical Prostatectomy and Extended Lymphadenectomy: Results of a Combined Molecular and Histopathologic Mapping Study. <i>European Urology</i> , 2014, 66, 222-229.	1.9	55
61	One-Stop-Shop Whole-Body ⁶⁸ Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1850-1856.	5.0	55
62	Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery. <i>European Urology Focus</i> , 2019, 5, 50-53.	3.1	52
63	Tumour volume delineation in prostate cancer assessed by [¹¹ C]choline PET/CT: validation with surgical specimens. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 824-831.	6.4	51
64	Patterns of failure after radical prostatectomy in prostate cancer – implications for radiation therapy planning after ⁶⁸ Ga-PSMA-PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1656-1662.	6.4	51
65	PET/MR in prostate cancer: technical aspects and potential diagnostic value. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 79-88.	6.4	49
66	Inpatient Comparison of ¹¹¹ In-PSMA I&T SPECT/CT and Hybrid ⁶⁸ Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e397-e402.	1.3	45
67	Evaluation of Computed Tomography for Lymph Node Staging in Bladder Cancer Prior to Radical Cystectomy. <i>Urologia Internationalis</i> , 2016, 96, 51-56.	1.3	45
68	Influence of Body Mass Index on Operability, Morbidity and Disease Outcome following Radical Cystectomy. <i>Urologia Internationalis</i> , 2009, 82, 432-439.	1.3	43
69	Chromogranin A and neuron-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy. <i>BJU International</i> , 2017, 119, 30-37.	2.5	42
70	Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction. <i>Journal of Nuclear Medicine</i> , 2020, 61, 234-241.	5.0	42
71	Minimal-Invasive Robot-Assisted Image-Guided Resection of Prostate-Specific Membrane Antigen-Positive Lymph Nodes in Recurrent Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, 580-581.	1.3	41
72	Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. <i>Journal of Hematology and Oncology</i> , 2014, 7, 20.	17.0	38

#	ARTICLE	IF	CITATIONS
73	Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?. <i>Bioconjugate Chemistry</i> , 2020, 31, 375-395.	3.6	38
74	The added value of PSMA PET/MR radiomics for prostate cancer staging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 527-538.	6.4	38
75	[⁶⁸ Ga]Ga-PSMA Versus [¹⁸ F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2022, 5, 273-282.	5.4	37
76	Robot-assisted Prostate-specific Membrane Antigen- ⁶⁸ radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study. <i>European Urology</i> , 2022, 82, 97-105.	1.9	37
77	Imaging for Prostate Cancer Recurrence. <i>European Urology Focus</i> , 2016, 2, 139-150.	3.1	36
78	Prospective head-to-head comparison of ¹¹ C-choline-PET/MR and ¹¹ C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2179-2188.	6.4	35
79	Histologically Confirmed Diagnostic Efficacy of ¹⁸ F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 710-715.	5.0	34
80	Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using ⁶⁸ Ga-PSMA PET/CT. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1632-1637.	5.0	33
81	⁶⁸ Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases. <i>Clinical Nuclear Medicine</i> , 2016, 41, e261-e262.	1.3	31
82	Prostate-Specific Membrane Antigen- ⁶⁸ Guided Surgery. <i>Journal of Nuclear Medicine</i> , 2020, 61, 6-12.	5.0	31
83	Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches. <i>International Journal of Cancer</i> , 2013, 133, 2145-2156.	5.1	28
84	Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands. <i>World Journal of Urology</i> , 2018, 36, 603-608.	2.2	28
85	A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2968-2977.	6.4	28
86	⁶⁸ Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1949-1955.	5.0	27
87	¹¹ C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer. <i>Oncotarget</i> , 2017, 8, 66516-66527.	1.8	25
88	Kinetic and Product Study of the Atmospheric Photooxidation of 1,4-Dioxane and Its Main Reaction Product Ethylene Glycol Diformate. <i>Journal of Physical Chemistry A</i> , 1999, 103, 5032-5039.	2.5	24
89	Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, E635-40.	2.5	23
90	Positron emission tomography/magnetic resonance imaging with ⁶⁸ Ga-labeled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging?. <i>International Journal of Urology</i> , 2014, 21, 1286-1288.	1.0	23

#	ARTICLE	IF	CITATIONS
91	Image of the Month. <i>Clinical Nuclear Medicine</i> , 2017, 42, 547-548.	1.3	23
92	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). <i>World Journal of Urology</i> , 2020, 38, 151-158.	2.2	23
93	Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2021, 79, 537-544.	1.9	23
94	Chemical Mechanism Development: Laboratory Studies and Model Applications. <i>Journal of Atmospheric Chemistry</i> , 2002, 42, 323-357.	3.2	22
95	Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study. <i>Journal of Urology</i> , 2021, 205, 1663-1670.	0.4	22
96	Prognostic value of computed tomography before radical cystectomy in patients with invasive bladder cancer: imaging predicts survival. <i>World Journal of Urology</i> , 2016, 34, 569-576.	2.2	21
97	PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 88-91.	5.0	21
98	Trifecta Outcomes of Partial Nephrectomy in Patients Over 75 Years Old: Analysis of the RENal SURGery in Elderly (RESURGE) Group. <i>European Urology Focus</i> , 2020, 6, 982-990.	3.1	20
99	Prognostic Value of ^{11}C -Choline PET/CT and CT for Predicting Survival of Bladder Cancer Patients Treated with Radical Cystectomy. <i>Urologia Internationalis</i> , 2014, 93, 207-213.	1.3	19
100	PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e549-e552.	1.9	19
101	^{68}Ga -PSMA PET/MR Showing Intense PSMA Uptake in Nodular Fasciitis Mimicking Prostate Cancer Metastasis. <i>Clinical Nuclear Medicine</i> , 2016, 41, e443-e444.	1.3	19
102	Bringing clarity or confusion? The role of prostate-specific membrane antigen positron emission/computed tomography for primary staging in prostate cancer. <i>BJU International</i> , 2017, 119, 194-195.	2.5	19
103	Extended versus limited pelvic lymph node dissection during bilateral nerve-sparing radical prostatectomy and its effect on continence and erectile function recovery: long-term results and trifecta rates of a comparative analysis. <i>World Journal of Urology</i> , 2016, 34, 811-820.	2.2	18
104	Non-invasive assessment of inter-and inpatient variability of integrin expression in metastasized prostate cancer by PET. <i>Oncotarget</i> , 2016, 7, 28151-28159.	1.8	18
105	Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 544.e1-544.e10.	1.6	16
106	Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer. <i>Current Opinion in Urology</i> , 2018, 28, 191-196.	1.8	16
107	Impact of ^{68}Ga -PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer. <i>Radiation Oncology</i> , 2018, 13, 36.	2.7	15
108	Utility of ^{18}F -rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1334-1342.	5.0	15

#	ARTICLE	IF	CITATIONS
109	68 Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block? Early or Too Early to Draw Conclusions?. <i>European Urology</i> , 2016, 70, 938-940.	1.9	13
110	Poor efficacy of BEP polychemotherapy in metastatic spermatocytic seminoma. <i>Medical Oncology</i> , 2011, 28, 423-425.	2.5	12
111	Intraoperative frozen section monitoring during nerve-sparing radical prostatectomy: evaluation of partial secondary resection of neurovascular bundles and its effect on oncologic and functional outcome. <i>World Journal of Urology</i> , 2016, 34, 229-236.	2.2	12
112	PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?. <i>Theranostics</i> , 2017, 7, 2046-2047.	10.0	12
113	Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection. <i>Clinical Cancer Research</i> , 2018, 24, 2342-2349.	7.0	12
114	PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. <i>EJNMMI Research</i> , 2021, 11, 76.	2.5	12
115	Positron emission tomography imaging in urological oncology: Current aspects and developments. <i>International Journal of Urology</i> , 2018, 25, 912-921.	1.0	10
116	Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1395-1401.	1.6	9
117	Current Staging Procedures in Urinary Bladder Cancer. <i>Diagnostics</i> , 2013, 3, 315-324.	2.6	9
118	Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study. <i>Infectious Agents and Cancer</i> , 2015, 10, 31.	2.6	9
119	Outcomes of Partial and Radical Nephrectomy in Octogenarians – A Multicenter International Study (Resurge). <i>Urology</i> , 2019, 129, 139-145.	1.0	9
120	The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancer. <i>World Journal of Urology</i> , 2014, 32, 359-363.	2.2	8
121	Correlation of tumor-associated macrophages and NK cells with bladder cancer size and T stage in patients with solitary low-grade urothelial carcinoma. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 248-252.	1.9	8
122	Gallium-68 HBED-CC-PSMA Positron Emission Tomography/Magnetic Resonance Imaging for Prostate Fusion Biopsy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 245-247.	1.9	8
123	Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e112-e121.	1.9	8
124	Final results of the PrAVAC trial: prevention of wound complications following inguinal lymph node dissection in patients with penile cancer using epidermal vacuum-assisted wound closure. <i>World Journal of Urology</i> , 2021, 39, 613-620.	2.2	8
125	KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 362-369.	3.9	8
126	Validation of ¹⁸ F-rhPSMA-7 and ¹⁸ F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1809-1814.	5.0	8

#	ARTICLE	IF	CITATIONS
127	Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 326-333.	1.9	8
128	Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 156-157.	5.0	7
129	Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent. <i>World Journal of Urology</i> , 2015, 33, 813-819.	2.2	6
130	PD32-07 PREOPERATIVE LYMPH NODE STAGING IN INTERMEDIATE TO HIGH-RISK PROSTATE CANCER PATIENTS USING 68GA-HBED-PSMA PET HYBRID IMAGING – A PATIENT- AND FIELD-BASED ANALYSIS. <i>Journal of Urology</i> , 2015, 193, .	0.4	6
131	Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis. <i>EJNMMI Research</i> , 2018, 8, 17.	2.5	6
132	Practice changing for prostate cancer: a vision of the future. <i>Nature Reviews Urology</i> , 2019, 16, 71-72.	3.8	6
133	PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 7.e1-7.e8.	1.6	6
134	Multimodal Tumor Therapy in a 31-Year-Old Pregnant Woman with Wilms Tumor. <i>Urologia Internationalis</i> , 2009, 83, 364-367.	1.3	5
135	Positive predictive value and correct detection rate of ¹⁸ F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.255661.	5.0	5
136	First Experience Using ¹⁸ F-Flubrobenguane PET Imaging in Patients with Suspected Pheochromocytoma or Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 479-485.	5.0	5
137	Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy – validation of a prediction model. <i>EJNMMI Research</i> , 2020, 10, 6.	2.5	5
138	PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5023-5023.	1.6	5
139	Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence. <i>European Urology Open Science</i> , 2021, 34, 55-58.	0.4	5
140	Rectal Swabs for Detecting Multidrug Resistant Bacteria Prior to Transrectal Prostate Fusion Biopsy: A Prospective Evaluation of Risk Factor Screening and Microbiologic Findings. <i>Urology</i> , 2020, 136, 127-132.	1.0	4
141	Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579). <i>BJU International</i> , 2021, 128, 301-303.	2.5	4
142	Chemical Mechanism Development: Laboratory Studies and Model Applications. , 2002, , 323-357.		4
143	The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer. <i>Journal of Bone Oncology</i> , 2012, 1, 88-94.	2.4	3
144	Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 344-357.	3.8	3

#	ARTICLE	IF	CITATIONS
145	Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 294-296.	3.1	3
146	Contemporary update of SPECT tracers and novelties in radioguided surgery: a perspective based on urology. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 215-228.	0.7	3
147	An Open Source Multimodal Image-Guided Prostate Biopsy Framework. <i>Lecture Notes in Computer Science</i> , 2014, , 1-8.	1.3	3
148	PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16038-e16038.	1.6	3
149	MP42-08 STAGING OF INTERMEDIATE AND HIGH-RISK PROSTATE CANCER USING WHOLE BODY 68GALLIUM-LABELLED LIGAND OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN PET/MRI. <i>Journal of Urology</i> , 2014, 191, .	0.4	2
150	Radio-guided-surgery of a paravertebral paraganglioma using I-123-MIBG. <i>Nuklearmedizin - NuclearMedicine</i> , 2018, 57, N2-N3.	0.7	2
151	MATISSE: Performance in laboratory, results of AIV in Paranal, and first results on sky. , 2018, , .		2
152	Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 344-357.	3.8	2
153	Does presence of bone metastases portend worsened prognosis in metastatic renal cell carcinoma? Analysis of the REMARCC (Registry of MetAstatic RCC) database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 655-655.	1.6	2
154	Feasibility of fluorescence imaging at microdosing using a hybrid PSMA tracer during robot-assisted radical prostatectomy in a large animal model. <i>EJNMMI Research</i> , 2022, 12, 14.	2.5	2
155	IMMUNOSTIMULATORY CPG-DNA AND PSA-PEPTIDE VACCINATION ELICITS PROFOUND CYTOTOXIC T CELL RESPONSES. <i>Journal of Urology</i> , 2009, 181, 185-185.	0.4	1
156	Use of multifunctional power electronic network controllers in smart distribution systems. , 2014, , .		1
157	MP82-10 PSMA-RADIOGUIDED SURGERY: INTRODUCING MOLECULAR SURGERY IN PATIENTS WITH RECURRENT PROSTATE CANCER. <i>Journal of Urology</i> , 2015, 193, .	0.4	1
158	Image-guided surgery: from classical techniques to novel aspects and approaches. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 187-189.	0.7	1
159	Implementation of radioguided surgery in prostate cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 202-214.	0.7	1
160	Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 206-206.	1.6	1
161	95 ENHANCING PROTEIN OR PEPTIDE BASED IMMUNOTHERAPY UTILIZING CPG-DNA MEDIATED ANTIGEN SHUTTELING. <i>Journal of Urology</i> , 2010, 183, .	0.4	0
162	1925 TUMOR CONFIGURATION OF PROSTATE CANCER (PCA) INFLUENCES THE SENSITIVITY OF [11 C]CHOLINE POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY (PET/CT). <i>Journal of Urology</i> , 2011, 185, .	0.4	0

#	ARTICLE	IF	CITATIONS
163	1897 LYMPH NODE STAGING OF BLADDER CANCER PATIENTS SCHEDULED FOR RADICAL CYSTECTOMY: CORRELATION OF HISTOPATHOLOGY AND RESULTS OF PRE-OPERATIVE [11 C]CHOLINE PET/CT. Journal of Urology, 2011, 185, .	0.4	0
164	680 PREDICTION OF FAVOURABLE OUTCOME AND RATIONAL INDICATION OF DOCETAXEL RECHALLENGE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER. Journal of Urology, 2012, 187, .	0.4	0
165	MP42-18 IMAGING OF RECLURRENT PROSTATE CANCER USING 68GALLIUM-LABELLED LIGAND OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN PET/CT AND PET/MRI. Journal of Urology, 2014, 191, .	0.4	0
166	PD32-06 DETECTION RATES OF 68GALLIUM-LABELLED LIGAND OF PSMA PET/CT AND PET/MRI IN 332 CONSECUTIVE PATIENTS WITH BIOCHEMICAL RECURRENCY AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.4	0
167	Preconditioned intensity-based prostate registration using statistical deformation models. , 2017, , .		0
168	Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?. Asian Journal of Urology, 2021, 8, 248-250.	1.2	0
169	Reply to Francesco Montorsi, Nicola Fossati, Carlo A. Bravi, Giorgio Gandaglia, Nazareno Suardi, and Alberto Brigantiâ€™s Letter to the Editor re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. Eur Urol 2021;79:537â€“44. Surgical Treatment of Local Recurrence Following Radical Prostatectomy: Reality or Illusion? European Urology, 2021, 79, e134.	1.9	0
170	Reply to Fabio C.M. Torricelli and Rafael F. Coelhoâ€™s Letter to the Editor re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. Eur Urol 2021;79:537â€“44. European Urology, 2021, 80, e58.	1.9	0
171	780: Effect of Erectile Nerve Reconstruction on Restoration of Erectile Function and Expression of NOS Isoforms. Journal of Urology, 2007, 177, 261-261.	0.4	0
172	Prediction of favorable outcome in a docetaxel rechallenge setting in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2012, 30, 68-68.	1.6	0
173	Abstract 428: Hypermethylation of GATA2 is validated as a marker of progression in non-muscle invasive bladder cancer. , 2016, , .		0
174	Biopsie und Targeting. , 2017, , 91-110.		0
175	PSMA-targeted imaging of prostate cancer: evolution of a success story. Asian Journal of Andrology, 2017, 19, 388.	1.6	0
176	Oncological and postoperative outcome of salvage PSMA-radioguided surgery in recurrent prostate cancer.. Journal of Clinical Oncology, 2018, 36, 270-270.	1.6	0
177	Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities. Nuklearmedizin - NuclearMedicine, 2021, 60, 417-424.	0.7	0
178	Precision surgery: the role of intra-operative real-time image guidance - outcomes from a multidisciplinary European consensus conference.. American Journal of Nuclear Medicine and Molecular Imaging, 2022, 12, 74-80.	1.0	0